Literature DB >> 10764654

Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation: evidence for tissue angiotensin-converting enzyme function.

R Morishita1, G H Gibbons, N Tomita, L Zhang, Y Kaneda, T Ogihara, V J Dzau.   

Abstract

It has been proposed that vascular angiotensin-converting enzyme (ACE) plays an important role in regulating vascular growth. Indeed, ACE inhibitors have been reported to prevent neointimal formation after vascular injury in a rat carotid artery model. However, classic pharmacological experiments cannot exclude the potential contributions of hemodynamics and the circulating renin-angiotensin system (RAS). In this study, we used antisense oligodeoxynucleotide (ODN) to obtain local blockade of vascular ACE expression without effects on systemic hemodynamics and circulating RAS. To increase the effectiveness of antisense action, we modified the hemagglutinating virus of Japan-liposome ODN delivery method by cotransfection with nuclear protein (high mobility group 1 [HMG-1]) and RNase H. In vitro experiments showed the enhanced efficacy of antisense ODN by cotransfection of HMG-1 and RNase H compared with ODN alone. In vivo transfection of antisense ACE ODNs into intact uninjured rat carotid artery resulted in a significant reduction of vascular ACE activity, and cotransfection of HMG-1 and RNase H showed further reduction. We examined the effects of local blockade of vascular ACE expression on neointimal formation after vascular injury. Transfection of antisense ACE ODNs resulted in the attenuation of neointimal formation, whereas sense and scrambled ODNs did not. Blood pressure, heart rate, and serum ACE activity were not affected by antisense treatment. The magnitude of vascular ACE inhibition correlated with the suppression of the neointimal size. Overall, this study demonstrates that local antisense ODN inhibition of vascular ACE expression attenuates neointimal formation independent of hemodynamics and circulating RAS. The results support the existence of a functional tissue angiotensin system in the rat vessel wall.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764654     DOI: 10.1161/01.atv.20.4.915

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

1.  Association between the molecular pathobiology of essential hypertension and thrombotic diseases.

Authors:  T S Edgington
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 2.  Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosis.

Authors:  Sung Won Youn; Kwan-Kyu Park
Journal:  Int J Mol Sci       Date:  2015-05-22       Impact factor: 5.923

3.  Local Augmented Angiotensinogen Secreted from Apoptotic Vascular Endothelial Cells Is a Vital Mediator of Vascular Remodelling.

Authors:  Shyh-Jong Wu; Mathilde Soulez; Ya-Hui Yang; Chih-Sheng Chu; Shih-Chuan Shih; Marie-Josée Hébert; Mei-Chuan Kuo; Ya-Ju Hsieh
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

Review 4.  AMPK: a balancer of the renin-angiotensin system.

Authors:  Jia Liu; Xuan Li; Qingguo Lu; Di Ren; Xiaodong Sun; Thomas Rousselle; Ji Li; Jiyan Leng
Journal:  Biosci Rep       Date:  2019-09-03       Impact factor: 3.840

Review 5.  Role of MicroRNA in Endothelial Dysfunction and Hypertension.

Authors:  Miruna Nemecz; Nicoleta Alexandru; Gabriela Tanko; Adriana Georgescu
Journal:  Curr Hypertens Rep       Date:  2016-12       Impact factor: 5.369

Review 6.  The Renin-Angiotensin-aldosterone system in vascular inflammation and remodeling.

Authors:  Maricica Pacurari; Ramzi Kafoury; Paul B Tchounwou; Kenneth Ndebele
Journal:  Int J Inflam       Date:  2014-04-06

7.  Rosuvastatin Reverses Hypertension-Induced Changes in the Aorta Structure and Endothelium-Dependent Relaxation in Rats Through Suppression of Apoptosis and Inflammation.

Authors:  Qingbo Lv; Yao Wang; Ya Li; Liding Zhao; Yingchao Gong; Meihui Wang; Min Wang; Guosheng Fu; Wenbin Zhang
Journal:  J Cardiovasc Pharmacol       Date:  2020-06       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.